Asiatic acid inhibits HBV cccDNA transcription by promoting HBx degradation

Virol J. 2024 Oct 28;21(1):268. doi: 10.1186/s12985-024-02535-3.

Abstract

Background: Hepatitis B virus (HBV) infection is a persistent global public health problem, and curing for chronic hepatitis B (CHB) through the application of existing antiviral drugs is beset by numerous challenges. The viral protein HBx is a critical regulatory factor in the life cycle of HBV. Targeting HBx is a promising possibility for the development of novel therapeutic strategies.

Methods: The Nano-Glo® HiBiT Lysis Detection System was used to screen the herbal monomer compound library for compounds that inhibit HBx expression. Western blotting was used to examine proteins expression. Southern blotting or Northern blotting were used to detect HBV DNA or HBV RNA. ELISA was performed to detect the HBsAg level. The effect of asiatic acid on HBV in vivo was investigated by using recombinant cccDNA mouse model.

Results: Asiatic acid, an extract of Centella asiatica, significantly reduced the HBx level. Mechanistic studies demonstrated that asiatic acid may promote the degradation of HBx in an autophagy pathway-dependent manner. Subsequently, asiatic acid was found to reduce the amount of HBx bound to covalently closed circular DNA (cccDNA) microchromosomes, and repressive chromatin modifications then occurred, ultimately inhibiting cccDNA transcriptional activity. Moreover, in HBV-infected cells and a mouse model of persistent HBV infection, asiatic acid exhibited potent anti-HBV activity, as evidenced by decreased levels of HBV RNAs, HBV DNA and HBsAg.

Conclusions: Asiatic acid was identified as a compound that targets HBx, revealing its potential for application as an anti-HBV agent.

Keywords: Asiatic acid; HBx; Hepatitis B virus.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • DNA, Circular* / genetics
  • DNA, Circular* / metabolism
  • DNA, Viral / genetics
  • Disease Models, Animal
  • Hepatitis B / drug therapy
  • Hepatitis B / virology
  • Hepatitis B virus* / drug effects
  • Hepatitis B virus* / genetics
  • Hepatitis B virus* / physiology
  • Humans
  • Mice
  • Pentacyclic Triterpenes* / pharmacology
  • Proteolysis / drug effects
  • Trans-Activators* / genetics
  • Trans-Activators* / metabolism
  • Transcription, Genetic / drug effects
  • Viral Regulatory and Accessory Proteins* / genetics
  • Viral Regulatory and Accessory Proteins* / metabolism
  • Virus Replication / drug effects

Substances

  • asiatic acid
  • Pentacyclic Triterpenes
  • Viral Regulatory and Accessory Proteins
  • Trans-Activators
  • hepatitis B virus X protein
  • DNA, Circular
  • Antiviral Agents
  • DNA, Viral

Grants and funding